Myovant Sciences Priced, NYSE: MYOV

Newly-formed biotech developing an acquired therapy for endocrine disorders.

Industry: Health Care

Latest Trade: $13.03 0.00 (0.0%)

First Day Return: -11.6%

Return from IPO: -13.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer.
more less
IPO News for Myovant Sciences
more
IPO Data
IPO File Date 09/30/2016
Offer Price $15.00
Price Range $12.00 - $15.00
Offer Shares (mm) 14.5
Deal Size ($mm) $218
IPO Data
IPO Date 10/26/2016
Offer Price $15.00
Price Range $12.00 - $15.00
Offer Shares (mm) 14.5
Deal Size ($mm) $218
Underwriters
more
Company Data
Headquarters Hamilton, Bermuda
Founded 2016
Employees 9
Website www.myovant.com